Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.
about
Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acidDiffusion-weighted magnetic resonance imaging in cancer: Reported apparent diffusion coefficients, in-vitro and in-vivo reproducibilityPrediction of liver cirrhosis, using diagnostic imaging tools.Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI.Three-Tesla magnetic resonance elastography for hepatic fibrosis: comparison with diffusion-weighted imaging and gadoxetic acid-enhanced magnetic resonance imaging.MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score.Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity.Decreases in molecular diffusion, perfusion fraction and perfusion-related diffusion in fibrotic livers: a prospective clinical intravoxel incoherent motion MR imaging studyHistogram analysis of gadoxetic acid-enhanced MRI for quantitative hepatic fibrosis measurementHepatobiliary contrast agents: differential diagnosis of focal hepatic lesions, pitfalls and other indications.Hepatitis C related chronic liver cirrhosis: feasibility of texture analysis of MR images for classification of fibrosis stage and necroinflammatory activity grade.Apparent diffusion coefficient measurements and Gd-DTPA enhanced-imaging in staging hepatic fibrosis in rats.Magnetization transfer MRI in pancreatic cancer xenograft models.Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models.Dynamic contrast-enhanced optical imaging of in vivo organ function.Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)Evaluation of hypointense liver lesions during hepatobiliary phase MR imaging in normal and cirrhotic livers: is increasing flip angle reliable?Feasibility of histogram analysis of susceptibility-weighted MRI for staging of liver fibrosisThe MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase.Gd-EOB-DTPA-enhanced MR relaxometry for the detection and staging of liver fibrosis.Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: Comparison between signal-intensity-based indices and T1 relaxometry.Histogram analysis of hepatobiliary phase MR imaging as a quantitative value for liver cirrhosis: preliminary observations.Liver MRI and histological correlates in chronic liver disease on multiphase gadolinium-enhanced 3D gradient echo imaging.Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI.Diffusion-weighted imaging of the liver: an update.Measuring hepatic functional reserve using low temporal resolution Gd-EOB-DTPA dynamic contrast-enhanced MRI: a preliminary study comparing galactosyl human serum albumin scintigraphy with indocyanine green retention.P4 radiology of hepatobiliary diseases with gadoxetic acid-enhanced MRI as a biomarker.Recent advances in estimating hepatic functional reserve in patients with chronic liver damage.Apparent diffusion coefficient value of hepatic fibrosis and inflammation in children with chronic hepatitis.Gadoxetic acid: pearls and pitfalls.Visual assessment of biliary excretion of Gd-EOB-DTPA in patients with suspected diffuse liver disease - A biopsy-verified prospective study.Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC.Liver-specific magnetic resonance contrast medium in the evaluation of chronic liver disease.Liver Fibrosis Quantification by Magnetic Resonance Imaging.Comparison of the effect of region-of-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis.Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?Multiparametric or practical quantitative liver MRI: towards millisecond, fat fraction, kilopascal and function era.Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.Liver Apparent Diffusion Coefficient Changes during Telaprevir-Based Therapy for Chronic Hepatitis C.Gadoxetic Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study.
P2860
Q26769602-ABEF0347-1DC6-42B4-9390-9DFD299B9C0EQ26770403-92725731-FC9A-4D52-8FE0-BA4366890BF7Q26795413-0793F50A-A09B-45C4-80A0-45D16DB4834BQ30422395-700736FE-C18A-4937-AAA3-EC5991418743Q30422941-D6F1682F-66EC-44BC-A32E-47F384B5762DQ33858748-B88793D5-29B9-4199-B562-E689C65263E1Q34506324-BB78879B-82C7-4DEB-835B-384B1C3ED8AAQ34600947-E029D527-9FCE-4E49-BF05-AB0F08ADDAD1Q34612486-DAC0566B-C92F-461F-BAA8-DE6BF9F34F86Q35124054-5AAF326A-FBA0-44A1-9DCE-1C620ED27077Q35152252-70EEBB01-B7F3-42A0-8A31-769C53EA1414Q35480134-1FF76E93-AE30-40A2-8BAE-84BFD7E2D027Q35881908-AD5518B1-64B6-4FE8-9696-05D44964E6B3Q36177218-35B98316-886D-4BED-9225-1BD7F7B75969Q36210818-E29955D7-FDCA-4F53-83BA-C4E691637859Q36423114-54BC7564-3628-49C9-AE61-E1D0A973C25BQ36432637-5C631316-EFAE-4E05-B92F-9147602A63ABQ37114820-4647E96B-8FDD-4481-97BE-D19B4CD3EE55Q37488806-44E6B02E-220F-4141-B455-047A349DC468Q37609582-6378CF7B-B7C2-4296-8AB4-6142846124DFQ37683854-4C1317FF-52F3-4C45-A88E-2CD831DD11B5Q37708229-9A1E3B72-DB0C-4680-AAAF-0D8E8E79C520Q38008252-6D28EDA9-83B0-42E2-B0C5-EAD2FECC8CAFQ38069066-EFAEECA9-0E3D-4C8C-9FEC-6F55D29448B4Q38100027-647805D2-E249-41E4-BD71-957132750F88Q38129312-0361269A-D997-4853-87FB-3AD8AF74E19EQ38177850-50AB1F41-BBA6-48F9-9B90-ED4C2E741147Q38194202-0833AB5F-10BF-4537-92D9-39BE6F410164Q38213277-CD4AE484-D480-4FA3-86A7-F7888CE9EEAEQ38329089-90A46E95-E94E-4089-955C-78E6E1631C75Q38367219-6DD36111-180B-44EC-BE6D-1512B9BE5413Q38368535-C13DFA32-7B4E-434C-8B72-5CE387894524Q38543942-DF215BD3-CBB0-486A-B1BC-5E3E9998281CQ38600259-E024635D-67C0-4D07-8EB9-40D8ACD21BA0Q38906069-47C1159A-9731-4F53-8DAF-6CD7C8E4188EQ39013059-C58A6030-255A-4248-ABA4-0172490DE34CQ39034532-90271DAF-486C-4103-B2BF-617F0A7761B3Q39380465-8FCE99EC-8902-4953-A5A0-CC1620367BF2Q40403305-6A5C8E18-B87D-4ADF-8AEE-FAD57154AF62Q40619693-119AAC42-7BC0-45CF-8D55-B0F8D88BC952
P2860
Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Staging hepatic fibrosis: comp ...... ing--preliminary observations.
@en
Staging hepatic fibrosis: comp ...... ing--preliminary observations.
@nl
type
label
Staging hepatic fibrosis: comp ...... ing--preliminary observations.
@en
Staging hepatic fibrosis: comp ...... ing--preliminary observations.
@nl
prefLabel
Staging hepatic fibrosis: comp ...... ing--preliminary observations.
@en
Staging hepatic fibrosis: comp ...... ing--preliminary observations.
@nl
P2093
P356
P1433
P1476
Staging hepatic fibrosis: comp ...... ing--preliminary observations.
@en
P2093
Haruo Watanabe
Hiroshi Kondo
Kyongtae T Bae
Masayuki Kanematsu
Minoru Onozuka
Noriyuki Moriyama
Satoshi Goshima
P304
P356
10.1148/RADIOL.10100621
P407
P577
2011-01-19T00:00:00Z